Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model
Clinical & Experimental Metastasis · 2024
DOI: 10.1007/s10585-024-10278-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical & Experimental Metastasis, 2024. Verfasst von Negar Pourjamal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Camptothecin. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Helsinki.
Abstract (Originalsprache)
Human epidermal growth factor 2 (HER2)-positive breast cancer with lung metastases resistant to targeted agents is a common therapeutic challenge. Absence of preclinical lung metastasis models that are resistant to multiple anti-HER2 targeted drugs hampers the development of novel therapies. We established a novel HER2-positive breast cancer cell line (L-JIMT-1) with a high propensity to form lung metastases from the parenteral JIMT-1 cell line by injecting JIMT-1 cells into immunodeficient SCID mice. Lung metastases developed in all mice injected with L-JIMT-1 cells, and more rapidly and in greater numbers compared with the parental JIMT-1 cells. L-JIMT-1 cells expressed more epidermal growth factor receptor and HER2 than JIMT-1 cells. L-JIMT-1 cells were resistant to all five tyrosine kinase inhibitors tested in vitro (afatinib, erlotinib, lapatinib, sapitinib, and tucatinib). When we compared JIMT-1 and L-JIMT-1 sensitivity to three HER2-targeting antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), and disitamab vedotin (DV) in vitro, JIMT-1 cells were resistant T-DXd, partially sensitive to T-DM1, and sensitive to DV, while L-JIMT-1 cells were resistant to both T-DM1 and T-DXd, but moderately sensitive to DV. In a mouse model, all three ADCs inhibited the growth of L-JIMT-1 lung metastases compared to a vehicle, but DV and T-DXd more strongly than T-DM1, and DV treatment led to the smallest tumor burden. The L-JIMT breast cancer lung metastasis model developed may be useful in the evaluation of anti-cancer agents for multiresistant HER2-positive advanced breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Laboratory of Molecular Oncology, University of Helsinki, Helsinki, Finland.
- Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Neuroscience Center, Helsinki Institute of Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland.
- Laboratory Animal Center, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
- Wihuri Research Institute, University of Helsinki, Helsinki, Finland.
Förderung
- University of Helsinki
Zitieren
APA
Pourjamal, N., Yazdi, N., Halme, A., Joncour, V. L., Laakkonen, P., Saharinen, P., Joensuu, H., & Barok, M. (2024). Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-024-10278-2
Vancouver
Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, et al. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. Clinical & Experimental Metastasis. 2024. doi:10.1007/s10585-024-10278-2
BibTeX
@article{Pourjamal2024,
author = {Pourjamal, Negar and Yazdi, Narjes and Halme, Aleksi and Joncour, Vadim Le and Laakkonen, Pirjo and Saharinen, Pipsa and Joensuu, Heikki and Barok, Mark},
title = {Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model},
journal = {Clinical & Experimental Metastasis},
year = {2024},
doi = {10.1007/s10585-024-10278-2}
}
EUVIMED